FDA 483 - Catalent Pharma Solutions LLC - September 28, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Catalent Pharma Solutions LLC in Morrisville, NC, revealed significant deficiencies in the firm's design control procedures for their Albuterol Sulfate Inhalation Aerosol, 90 µg combination device. The company failed to adequately establish and maintain plans and procedures for design validation, verification, input, output, and overall design and development activities. These observations indicate a systemic lack of adherence to regulatory requirements for combination product design controls.
ID · d05d9a0f-3217-4bac-94c9-f97a63c84ecd